Crucial Role of P53-dependent Cellular Senescence in Suppression of Pten-deficient Tumorigenesis

Overview

Journal Nature

Specialty Science

Date 2005 Aug 5

PMID 16079851

Citations 1023

Authors

Zhenbang Chen

Lloyd C Trotman

David Shaffer

Hui-Kuan Lin

Zohar A Dotan

Masaru Niki

Jason A Koutcher

Howard I Scher

Thomas Ludwig

William Gerald

Carlos Cordon-Cardo

Pier Paolo Pandolfi

Affiliations

Soon will be listed here.

Abstract

Cellular senescence has been theorized to oppose neoplastic transformation triggered by activation of oncogenic pathways in vitro, but the relevance of senescence in vivo has not been established. The PTEN and p53 tumour suppressors are among the most commonly inactivated or mutated genes in human cancer including prostate cancer. Although they are functionally distinct, reciprocal cooperation has been proposed, as PTEN is thought to regulate p53 stability, and p53 to enhance PTEN transcription. Here we show that conditional inactivation of Trp53 in the mouse prostate fails to produce a tumour phenotype, whereas complete Pten inactivation in the prostate triggers non-lethal invasive prostate cancer after long latency. Strikingly, combined inactivation of Pten and Trp53 elicits invasive prostate cancer as early as 2 weeks after puberty and is invariably lethal by 7 months of age. Importantly, acute Pten inactivation induces growth arrest through the p53-dependent cellular senescence pathway both in vitro and in vivo, which can be fully rescued by combined loss of Trp53. Furthermore, we detected evidence of cellular senescence in specimens from early-stage human prostate cancer. Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours.

Citing Articles

Natural Product-Derived Senotherapeutics: Extraction and Biological Evaluation Techniques.

Pratsinis H, Mavrogonatou E, Zervou S, Triantis T, Hiskia A, Kletsas D Methods Mol Biol. 2025; 2906:315-359.

PMID: 40082365 DOI: 10.1007/978-1-0716-4426-3_19.

H2AJ Is a Direct Androgen Receptor Target Gene That Regulates Androgen-Induced Cellular Senescence and Inhibits Mesenchymal Markers in Prostate Cancer Cells.

Heidari Horestani M, Atri Roozbahani G, Baniahmad A Cancers (Basel). 2025; 17(5).

PMID: 40075640 PMC: 11898987. DOI: 10.3390/cancers17050791.

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.

The complex interplay between aging and cancer.

Trastus L, dAdda di Fagagna F Nat Aging. 2025; .

PMID: 40038418 DOI: 10.1038/s43587-025-00827-z.

TP53 Deficiency in the Natural History of Prostate Cancer.

Ofner H, Kramer G, Shariat S, Hassler M Cancers (Basel). 2025; 17(4).

PMID: 40002239 PMC: 11853097. DOI: 10.3390/cancers17040645.

References

Hermans K, van Alewijk D, Veltman J, van Weerden W, Geurts van Kessel A, Trapman J . Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes Cancer. 2004; 39(3):171-84. DOI: 10.1002/gcc.10311. View

Mayo L, Donner D . A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001; 98(20):11598-603. PMC: 58775. DOI: 10.1073/pnas.181181198. View

Stewart S, King J, Thompson T, Friedman C, Wingo P . Cancer mortality surveillance--United States, 1990-2000. MMWR Surveill Summ. 2004; 53(3):1-108. View

Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C . Leveling of prostate cancer mortality in Western Europe. Prostate. 2004; 60(1):46-52. DOI: 10.1002/pros.20058. View

Campisi J . Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 2001; 11(11):S27-31. DOI: 10.1016/s0962-8924(01)02151-1. View

Dimri G, Lee X, Basile G, Acosta M, Scott G, Roskelley C . A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92(20):9363-7. PMC: 40985. DOI: 10.1073/pnas.92.20.9363. View

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

Stambolic V, Macpherson D, Sas D, Lin Y, Snow B, Jang Y . Regulation of PTEN transcription by p53. Mol Cell. 2001; 8(2):317-25. DOI: 10.1016/s1097-2765(01)00323-9. View

Freeman D, Li A, Wei G, Li H, Kertesz N, Lesche R . PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003; 3(2):117-30. DOI: 10.1016/s1535-6108(03)00021-7. View

10.

Abate-Shen C, Shen M . Molecular genetics of prostate cancer. Genes Dev. 2000; 14(19):2410-34. DOI: 10.1101/gad.819500. View

11.

Serrano M, Blasco M . Putting the stress on senescence. Curr Opin Cell Biol. 2001; 13(6):748-53. DOI: 10.1016/s0955-0674(00)00278-7. View

12.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

13.

Weinberg R . The cat and mouse games that genes, viruses, and cells play. Cell. 1997; 88(5):573-5. DOI: 10.1016/s0092-8674(00)81897-8. View

14.

Di Cristofano A, Pandolfi P . The multiple roles of PTEN in tumor suppression. Cell. 2000; 100(4):387-90. DOI: 10.1016/s0092-8674(00)80674-1. View

15.

Wu X, Wu J, Huang J, Powell W, Zhang J, Matusik R . Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001; 101(1-2):61-9. DOI: 10.1016/s0925-4773(00)00551-7. View

16.

Qian J, Hirasawa K, Bostwick D, Bergstralh E, Slezak J, Anderl K . Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 2002; 15(1):35-44. DOI: 10.1038/modpathol.3880487. View

17.

Lowe S, Cepero E, Evan G . Intrinsic tumour suppression. Nature. 2004; 432(7015):307-15. DOI: 10.1038/nature03098. View

18.

Schmitt C, Fridman J, Yang M, Lee S, Baranov E, Hoffman R . A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002; 109(3):335-46. DOI: 10.1016/s0092-8674(02)00734-1. View

19.

Suzuki H, Freije D, Nusskern D, Okami K, Cairns P, Sidransky D . Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998; 58(2):204-9. View

20.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View